In vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Carbapenem-resistant Enterobacteriaceae Isolates Collected from Three Secondary Hospitals in Southwest China Between 2018 and 2019

Figures & data

Table 1 Species Distribution Among CRE and CPE

Species	CRE	CPE by Hospital (n)
		Total	Hospital A	Hospital B	Hospital C
K. pneumoniae	92	80	39	18	23
E. coli	10	8	4	4	0
E. cloacae	10	9	6	3	0
K. aerogenes	5	3	0	0	3
K. oxytosus	3	3	0	3	0
Total	120	103	49	28	26

Table 2 Prevalence of Carbapenamase Genotype by Hospital

Gene	Total (n)	Hospital A (n)	Hospital B (n)	Hospital C (n)
blaKPC-2	74	34	14	26
blaKPC-2, blaNDM-1	3	2	1	0
blaNDM-1	12	4	8	0
blaNDM-1, blaIMP-4	1	1	0	0
blaIMP-4	1	0	1	0
blaNDM-5	12	8	4	0

Table 3 In vitro Susceptibility of Different Antibiotics Against 120 CRE Isolates

Antimicrobial Agent	Total n	Resistance n (%)	MIC (mg/L)
			Range	MIC50	MIC90
Ceftazidime	120	120 (100.0)	16–≥128	≥128	≥128
Ceftazidime-avibactam	120	30 (25.0)	0.125–>256	1	256
Aztreonam	120	116 (96.7)	≤1–≥128	≥128	≥128
Aztreonam-avibactam	120	0 (0)	≤0.125–4	≤0.125	1
Ertapenem	120	120 (100.0)	4–512	256	512
Imipenem	120	103 (85.8)	0.5–512	64	256
Meropenem	120	98 (81.7)	0.25–256	64	128
Gentamicin	120	78 (65.0)	≤1–≥128	≥128	≥128
Amikacin	120	71 (59.2)	≤2–≥64	≥64	≥64
Levofloxacin	120	94 (78.3)	≤0.125–≥8	4	≥8
Ciprofloxacin	120	94 (78.3)	≤0.125–≥16	8	≥16
Sulfamethoxazole-trimethoprim	120	75 (62.5)	≤0.5–≥16	8	≥16